Third Party Agreements - Additional Information (Details) - USD ($) $ in Millions |
6 Months Ended | |
|---|---|---|
Jan. 28, 2022 |
Jun. 30, 2024 |
|
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||
| Research and development in process 1 | $ 1.0 | |
| License agreement termination description | twelve (12) years | |
| Regeneron Pharmaceuticals, Inc. | ||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||
| Revenue recognized | $ 5.0 | |
| Exercise Fee Paid | $ 20.0 | 20.0 |
| Licence agreement additional revenue recognised | 25.0 | |
| Non refundable upfront payment received | 25.0 | |
| Additional payment for research funding received | 20.0 | |
| Regeneron Pharmaceuticals, Inc. | Maximum | ||
| Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] | ||
| Licence agreement additional amount payable of option exercise fees | $ 80.0 |